Aripiprazole and Effexor XR Drug Interaction Study
Overview
The purpose of this clinical research study is to learn whether aripiprazole has effect on the steady-state pharmacokinetics of venlafaxine in healthy subjects. The safety and tolerability of aripiprazole and venlafaxine co-administration will also be studied.
Full Title of Study: “Effects of Aripiprazole on the Steady-State Pharmacokinetics of Venlafaxine in Healthy Subjects”
Study Type
- Study Type: Interventional
- Study Design
- Allocation: Non-Randomized
- Intervention Model: Single Group Assignment
- Masking: None (Open Label)
- Study Primary Completion Date: September 2006
Interventions
- Drug: Venlafaxine on Day -4 to day 14, Aripiprazole dosed starting on Day 1: 3 days at 10 mg, 4 days at 1 mg and 7 days at 20 mg.
- Tablets, Oral, Venlafaxine: 75 mg; Aripiprazole: 10, 15, 20 mg once daily, 14 days.
Arms, Groups and Cohorts
- Other: 1
Clinical Trial Outcome Measures
Primary Measures
- Multiple dose PK parameters for venlafaxine+metabolite when administered alone and with aripiprazole will be derived. Cmin for aripiprazole,dehydro-aripiprazole will be measured
Secondary Measures
- Safety will be based on review of AEs, VS, ECGs, physical exam, clinical labs
Participating in This Clinical Trial
Inclusion Criteria
- Healthy male and female subjects, ages 18 to 45 (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 4 weeks after the study in such a manner that the risk of pregnancy is minimized. – Body Mass Index (BMI) of 18 to 33 kg/m2, inclusive. Exclusion Criteria:
- Subjects with a decrease in SBP of >=20 mm Hg and increase in HR of >=20 bpm after 2 minutes standing vs. 2 minutes supine at screening or with frank orthostatic hypotension at screening. – Supine BP of 90/50 mm Hg or lower at screening – SBP >=140 mm Hg or DBP >=90 mm Hg at screening
Gender Eligibility: All
Minimum Age: 18 Years
Maximum Age: 45 Years
Are Healthy Volunteers Accepted: Accepts Healthy Volunteers
Investigator Details
- Lead Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Overall Official(s)
- Bristol-Myers Squibb, Study Director, Bristol-Myers Squibb
Clinical trials entries are delivered from the US National Institutes of Health and are not reviewed separately by this site. Please see the identifier information above for retrieving further details from the government database.